Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine D3 receptor

Details for Australian Patent Application No. 2005311452 (hide)

Owner Abbott GmbH & Co. KG

Inventors Turner, Sean C.; Haupt, Andreas; Darbyshire, John; Drescher, Karla; Backfisch, Gisela; Unger, Liliane; Beyerbach, Armin; Braje, Wilfried

Agent Spruson & Ferguson

Pub. Number AU-A-2005311452

PCT Pub. Number WO2006/058753

Priority 60/632,412 02.12.04 US

Filing date 1 December 2005

Wipo publication date 8 June 2006

International Classifications

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

19 July 2007 PCT application entered the National Phase

  PCT publication WO2006/058753 Priority application(s): WO2006/058753

19 November 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005311457-Nutrition bar

2005311451-[1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases